Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SAMUFLU

Financiado

Cerrado

Self amplifying RNA technology applied to the development of a universal influen...

Self amplifying RNA technology applied to the development of a universal influenza vaccine Influenza (Flu) virus infections lead to thousands of deaths annually worldwide and billions of dollars of economic burden. Vaccination is the primary strategy for Flu prevention; however, effective protection requires a perfect m... ver más

31/03/2016

GSK Vaccines Srl

187K€

Presupuesto del proyecto: 187K€

Líder del proyecto

GlaxoSmithKline Vaccines Srl No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-03-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GSK Vaccines Srl

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

UNIFLUVAC A novel universal influenza vaccine targeting epitopes of li... 149K€ Cerrado

UNIVACFLU Universal Flu Vaccine 4M€ Cerrado

FLUniversal Intranasal, rapid-acting vaccine for all seasonal and pandem... 8M€ Cerrado

AGL2010-22200-C02-02 CARACTERIZACION DE LA RESPUESTA INMUNE INDUCIDA POR CEPAS DE... 157K€ Cerrado

PGC2018-099341-B-I00 CARACTERIZACION DE LA DINAMICA TRANSCRIPCIONAL DEL VIRUS DE... 191K€ Cerrado

FLUTCORE Development of a universal influenza vaccine based on tandem... 4M€ Cerrado

Líder del proyecto

GlaxoSmithKline Vaccines Srl No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 187K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Influenza (Flu) virus infections lead to thousands of deaths annually worldwide and billions of dollars of economic burden. Vaccination is the primary strategy for Flu prevention; however, effective protection requires a perfect match with the seasonal circulating strains. Seasonal vaccines target the hemagglutinin (HA) and neuraminidase (NA) proteins of the two predominant A and one B circulating strains, and induce high neutralizing antibody titers. Emerging Flu viruses escape host immunity by modifying HA glycosylation and masking the immunodominant epitopes of previous years’ strains. In consequence, yearly seasonal Flu vaccines have to be developed. Therefore, there is a need for a universal Flu vaccine that would protect against most variants. Patterns of HA glycosylation show that there are only 5 – 6 alterations in a century of evolution, reflecting the limited possibilities for the virus to escape host immunity while retaining its infectivity. Therefore, by developing a vaccine that includes most relevant past seasonal (H1, H3, and B) and pandemic (H5, H7) strains, it might be feasible to develop a universal Flu vaccine. The project will combine HA selection with the novel self-amplifying mRNA (SAM®) vaccine technology, which consists of a synthetic RNA delivered by lipid nanoparticles, and already proved immunogenic in mice with Flu H1 and H7. We will design five SAM(HA) vectors encoding combinations of four HA, prioritized to cover up to 20 relevant strains, and characterize their immunogenicity in mice by measuring hemagglutination-inhibition and virus neutralization titers. In-depth characterization of germinal center B cells and follicular helper T cells will be performed by mass cytometry (CyTOF). Finally, HA-specific CD4 and CD8 T-cell cytokine and cytotoxic responses will be determined by mass cytometry for correlates of protection. At the end of this proposal, the development of a universal Flu vaccine should be achieved.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores